Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-3 (BRII-196 and BRII-198), 2021 NCT04501978

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) (n=179) vs. placebo (n=183)

randomized controlled trial   low risk of bias

Studied treatment

BRII-196 plus BRII-198

Control treatment

Placebo

Randomisation allocation was 2:1:2:1 to sotrovimab, matching placebo for sotrovimab, BRII-196 plus BRII-198, or matching placebo for BRII-196 plus BRII-198. The concurrent placebo groups were pooled for analyses, resulting in approximately a 1:1:1 allocation ofsotrovimab to BRII-196 plus BRII-198 to placebo. All patients received remdesivir. Other treatments for COVID-19, including oxygen, respiratory support, and corticosteroids, were administered at the discretion of the treating clinician per local standard of care.

Patients

COVID 19 hospitalized

Method

Double-blind.

43 hospitals in the USA, Denmark, Switzerland, and Poland.

Remark

Prematurely discontinued for futility (based on pulmonary and pulmonary-plus ordinal outcome scale at day 5) after enrollment of 300 patients. *Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*